CVVT

In a major translational achievement for Hong Kong’s biomedical innovation sector, the Centre for Virology, Vaccinology and Therapeutics (CVVT) is pleased to highlight significant progress in the development of ICVAX®, a novel therapeutic DNA vaccine aiming to achieve a functional cure for HIV. Led by Prof. Zhiwei Chen, Deputy Director of CVVT, Director of the AIDS Institute at the LKS Faculty of Medicine, The University of Hong Kong (HKUMed), and Chair Professor of Immunology and...

The ongoing evolution of SARS-CoV-2, particularly the rapid emergence of the Omicron variant and its sub-lineages, has weakened the effectiveness of existing vaccines and antiviral drugs, underscoring the potential risk of future coronavirus pandemics. In response, a joint research team featuring leadership from the Centre for Virology, Vaccinology and Therapeutics (CVVT) with their team at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) as well as the School of...

A groundbreaking study led by BiomOrgan Limited, a spin-off company from the Centre for Virology, Vaccinology and Therapeutics (CVVT), has leveraged its proprietary respiratory organoids to provide a novel platform for developing influenza vaccines and antibodies. They revealed a critical human immune mechanism that provides natural cross-protection against emerging H5N1 influenza viruses, including the cattle-associated clade 2.3.4.4b strain. The study was spearheaded by Prof. Zhou Jie...